Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis - Top-Institutions - MDSpire

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

  • By

  • Xiaofan Liao

  • Xian Huang

  • Guilan Yang

  • Xia Wang

  • Qifeng Li

  • Yuan Lu

  • May 8, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Dermatology
    • Amyloidosis

  • #2

    Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center
    Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center

    Boston, Massachusetts

    Key Differentiators

    • Dermatology
    • Amyloidosis

  • #3

    University of Pittsburgh
    University of Pittsburgh

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Dermatology

Original Source(s)

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

  • by Xiaofan Liao, Xian Huang, Guilan Yang, Xia Wang, Qifeng Li, Yuan Lu

  • May 8, 2026

Related Content

Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.